ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
SIP-SRS Imaging of Cell Wall Synthesis Identifies a Synergy between Micafungin and Amphotericin B.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SIP-SRS Imaging of Cell Wall Synthesis Identifies a Synergy between Micafungin and Amphotericin B.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Candida species causes life-threatening infections in immunocompromised individuals and presents a formidable challenge in clinical practice. This challenge is exacerbated by the growing prevalence of drug resistance, particularly against the last resort antifungals such as amphotericin B (AmB). The fungal cell wall, known for its dynamic reorganization in response to growth demands and host threats, are recognized as a key drug target. In this study, stable isotope probe-assisted SRS microscopy (SIP-SRS) is harnessed to directly visualize and interrogate the dynamics of fungal cell wall synthesis under various antifungal treatments. A striking observation is the thickening of the cell wall in newly synthesized daughter cells under AmB treatment. Based on this finding, a synergistic inhibition of fungal growth is demonstrated by AmB and micafungin, an antifungal agent targeting cell wall synthesis. These results not only advance the understanding of fungal physiology at the molecular level but also open promising avenues for combating drug-resistant fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.